Literature DB >> 21708084

Factors predictive of radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma.

Hatem Krema1, Wei Xu, David Payne, Luz Maria Vasquez, Charles J Pavlin, Rand Simpson.   

Abstract

OBJECTIVE: To report the host, tumour, and radiation-related predictive factors for developing radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma.
DESIGN: A retrospective clinical case series. PARTICIPANTS: Three hundred consecutive patients with uveal melanoma treated with (125)Iodine brachytherapy.
METHODS: Electronic chart review of demographic, clinical, treatment, and follow-up data. Proliferative and (or) nonproliferative radiation retinopathy patients were included. Cumulative incidence rates were calculated using Kaplan-Meier estimates. Univariate and multivariate statistical regression analyses were performed to identify factors predictive of radiation retinopathy.
RESULTS: The mean follow-up period was 48 months. Radiation retinopathy occurred in 107 patients (36%). Actuarial incidence of radiation retinopathy was 30% (CI 24%-36%) at 24 months post-treatment. In the multivariate model, the predictive factors were a younger age (hazard ratio [HR] 0.98, p < 0.03), diabetes (HR 2.17, p < 0.007), and hypertension (HR 2.17, p < 0.004). Tumour-related factors were proximity to optic disc (HR 0.95, p < 0.02) and proximity to foveola (HR 0.96, p < 0.02). Pretreatment tumour dimensions, other tumour characteristics, and total radiation dose did not demonstrate statistically significant risks for developing radiation retinopathy.
CONCLUSIONS: Radiation retinopathy affects 30% of patients 2 years following (125)Iodine brachytherapy for uveal melanoma. The predictive factors for radiation retinopathy are a younger age, comorbidity with diabetes or hypertension, and proximity of the tumour margin to the optic disc or foveola. Identifying the predictive factors for developing radiation retinopathy can modify follow-up for patients at risk, which may permit earlier management of the developing radiation-induced ischemic retinal changes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21708084     DOI: 10.3129/i10-111

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  5 in total

1.  PAMM and the ischemic cascade associated with radiation retinopathy.

Authors:  Derrick Wang; Adrian Au; Jay S Duker; David Sarraf
Journal:  Am J Ophthalmol Case Rep       Date:  2020-09-08

2.  Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-08-31

3.  Silicone Oil and Iodine-125 Brachytherapy for Uveal Melanoma in High-Risk Patients.

Authors:  Lance J Lyons; Ethan D Hinds; Sarada Chexal; Brian Berger
Journal:  Cureus       Date:  2019-07-29

4.  Prophylactic Intravitreal Bevacizumab After Plaque Radiotherapy for Uveal Melanoma: Analysis of Visual Acuity, Tumor Response, and Radiation Complications in 1131 Eyes Based on Patient Age.

Authors:  Michael Chang; Lauren A Dalvin; Mehdi Mazloumi; Andrei Martin; Antonio Yaghy; Xiaolu Yang; Saba Bakhtiari; Lucy Li; Erin Jennings; Arman Mashayekhi; Carol L Shields
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2020 Jan-Feb

5.  Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma.

Authors:  Luca Tagliaferri; Monica Maria Pagliara; Carlotta Masciocchi; Andrea Scupola; Luigi Azario; Gabriela Grimaldi; Rosa Autorino; Maria Antonietta Gambacorta; Antonio Laricchiuta; Luca Boldrini; Vincenzo Valentini; Maria Antonietta Blasi
Journal:  J Contemp Brachytherapy       Date:  2017-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.